AVITA Medical Inc

AVITA Medical, Inc. through its subsidiaries, engages in the development and commercialization of technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product RECELL system is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company is headquartered in Valencia, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AVITA Medical Inc reports robust Q4 earnings and growth outlook

AVITA Medical's strong financial performance in Q4 2022 and full year 2022, coupled with strategic initiatives and growth projections for 2023, position the company for continued success.
While facing challenges in managing expenses and achieving regulatory approvals, AVITA Medical's focus on innovation, market expansion, and operational efficiency presents opportunities for sustained growth.
Investors should monitor the company's progress in securing PMA approvals, expanding market presence, and optimizing operational costs to capitalize on the projected revenue growth and market opportunities.

AVITA Medical reports robust Q1 earnings, eyes FDA approvals

AVITA Medical Inc. delivered strong financial results in Q1 2023, driven by revenue growth and operational improvements.
The company's strategic priorities for 2023 are on track, with pending FDA applications and new product launches in the pipeline.
While facing challenges in operational transitions and market competition, AVITA Medical remains focused on innovation and growth.

AVITA Medical reports strong Q2 performance with FDA milestones

AVITA Medical had a strong quarter with revenue growth and landmark FDA approvals.
The company faces challenges with increased expenses and supply chain issues.
Opportunities lie in market expansion, new FDA approvals, and international growth strategies.
AVITA Medical aims for realistic growth, focusing on hitting guidance targets to build credibility.

AVITA Medical reports robust revenue growth and strategic international expansion

AVITA Medical Inc's Q3 2023 performance reflects strong revenue growth and strategic initiatives to drive international expansion and profitability by 2025.
The company's focus on core business areas, confidence in growth prospects, and commitment to enhancing patient outcomes position it well for future success.
While facing challenges in pricing strategies and global expansion pace, AVITA Medical is poised to capitalize on opportunities in wound care innovation, regulatory approvals, and international market expansion.

AVITA Medical reports strong earnings, eyes global expansion and profitability

AVITA Medical Inc showcased robust financial performance and strategic advancements in Q4 2023 earnings call.
While facing challenges such as net losses and restructuring, the company is well-positioned for growth.
Opportunities lie in product launches, global expansion, and operational efficiency improvements.
Overall, AVITA Medical's performance and outlook signal a promising trajectory for future success.

AVITA Medical Inc reports Q1 revenue miss, eyes profitability by 2025

AVITA Medical Inc faced challenges in Q1 2024 with revenue falling short of expectations, but the company remains focused on strategic initiatives to drive growth and expand its product portfolio. Despite challenges, AVITA is optimistic about its international expansion efforts and aims to achieve profitability by the third quarter of 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product, RECELL system, is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company was founded in December 1992 and is headquartered in Valencia, CA.

Avita Medical Inc. (RCEL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Here's Why Momentum in Avita Medical Inc. (RCEL) Should Keep going

VALENCIA, Calif. and MELBOURNE, Australia, April 20, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today that it will report its first quarter 2023 financial results after the close of the U.S. financial markets on Thursday, May 11, 2023. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, May 12, 2023, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent business highlights.

AVITA Medical to Announce First Quarter 2023 Financial Results

Does Avita Medical Inc. (RCEL) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Avita Medical Inc. (RCEL) a Strong Momentum Stock: Buy Now?

VALENCIA, Calif. and MELBOURNE, Australia, April 13, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today that its automated device, RECELL GO, maintains the Food and Drug Administration (FDA) Breakthrough Device designation for the treatment of acute wounds. RECELL GO represents an evolution of the existing RECELL technology and is designed to automate the process of cell disaggregation.

AVITA Medical Announces Update to Automation Device

VALENCIA, Calif. and MELBOURNE, Australia, March 23, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today the appointment of Robert McNamara to its Board of Directors, effective April 1, 2023.

AVITA Medical Appoints New Non-Executive Member to the Board of Directors

After recovering from a long slide, Avita is no longer an obvious bargain. Avita's two upcoming FDA decisions could boost revenues as early as 07/2023, with a second stage boost in 01/2025.

AVITA Medical: At A Crossroads

What Makes Avita Medical Inc. (RCEL) a Good Fit for 'Trend Investing'

The mean of analysts' price targets for Avita Medical Inc. (RCEL) points to a 27.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in Avita Medical Inc. (RCEL)? Wall Street Analysts Think 27.42%

VALENCIA, Calif. and MELBOURNE, Australia, March 02, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today that Jim Corbett, Chief Executive Officer, will present at the TD Cowen 43rd Annual Health Care Conference in Boston on Tuesday, March 7, 2023, at 9:10 a.m. Eastern Time.

AVITA Medical to Present at the TD Cowen 43rd Annual Health Care Conference

Here's Why 'Trend' Investors Would Love Betting on Avita Medical Inc. (RCEL)

AVITA Medical, Inc. (NASDAQ:RCEL ) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Caroline Corner - Managing Director, Investor Relations Jim Corbett - Chief Executive Officer Sean Ekins - Acting Chief Financial Officer Conference Call Participants Joshua Jennings - Cowen Phillip Dantoin - Piper Brooks O'Neil - Lake Street Capital Markets Lyanne Harrison - Bank of America Operator Good day and thank you for standing by. Welcome to AVITA Medical Fourth Quarter 2022 Earnings Conference Call.

AVITA Medical, Inc. (RCEL) Q4 2022 Earnings Call Transcript

VALENCIA, Calif. and MELBOURNE, Australia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today reported financial results for the fourth quarter and full-year ended December 31, 2022.

AVITA Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance

VALENCIA, Calif. and MELBOURNE, Australia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today that it will report its fourth quarter and full year 2022 financial results after the close of the U.S. financial markets on Thursday, February 23, 2023. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, February 24, 2023, at 8:30 a.m. Australian Eastern Daylight Time) to discuss its financial results, business highlights, and 2023 revenue guidance.

AVITA Medical to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide 2023 Financial Guidance

Avita Medical Inc. (RCEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Avita Medical Inc. (RCEL) Stock Jumps 6.2%: Will It Continue to Soar?

Shares have fallen by 83% over the past 3 years and are down 13% over the past year. Q3 "beat and raise" along with appointment of a highly experienced CEO could turn sentiment around here.

AVITA Medical: Experienced CEO Taking The Helm As Expansion Opportunities Await

VALENCIA, Calif. and MELBOURNE, Australia, Jan. 19, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical” or the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today changes to its management structure designed to advance its strategic growth plans and accelerate execution under recently appointed Chief Executive Officer, James Corbett. To align with AVITA Medical's new operating structure, the following organizational changes will be effective January 19, 2023:

AVITA Medical Announces Management Changes and Fourth Quarter 2022 Earnings Conference Call

VALENCIA, Calif., and MELBOURNE, Australia, Dec. 19, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today the submission of a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its RECELL® System. The application, if approved, will expand the indication of RECELL to include the treatment of stable vitiligo.

AVITA Medical Submits FDA PMA Application to Expand Indication to Vitiligo

Avita has a modest existing business selling its skin regeneration products. Its shares have dropped recently despite several successes with the FDA.

Avita: Micro-Cap With Big Time Approvals On Near Horizon

VALENCIA, Calif. and MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced the results of its 2022 Annual Meeting of Stockholders, which was held virtually on December 12, 2022 (United States) (being December 13, 2022 in Australia).

AVITA Medical Announces Results of 2022 Annual Meeting of Stockholders

VALENCIA, Calif., and MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today the submission of a Premarket Approval (PMA) supplement application to the U.S. Food and Drug Administration (FDA) for the company's RECELL® System. The supplement, if approved, will expand the indication of RECELL to include soft tissue repair.

AVITA Medical Submits FDA PMA Supplement to Further Expand Indication to Soft Tissue Repair

VALENCIA, Calif., and MELBOURNE, Australia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today that its management team will present at the Piper Sandler 34th Annual Healthcare Conference in New York on Wednesday, November 30, 2022, at 4:30 p.m. Eastern Time.

AVITA Medical® to Present at the Piper Sandler 34th Annual Healthcare Conference

VALENCIA, Calif. and MELBOURNE, Australia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, CEO, and Michael Holder, CFO, on November 23, 2022 at 4:00pm (PST) / November 24, 2022 at 11:00am (AEDT).

AVITA Medical® to Host Investor Webinar Briefing

The average of price targets set by Wall Street analysts indicates a potential upside of 127.1% in Avita Medical Inc. (RCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 127% Upside in Avita Medical Inc. (RCEL): Can the Stock Really Move This High?

AVITA Medical, Inc. (NASDAQ:RCEL ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Caroline Corner - Managing Director, Investor Relations Jim Corbett - Chief Executive Officer Michael Holder - Chief Financial Officer Conference Call Participants Charlie Montang - Lake Street Capital Matthew O'Brien - Piper Sandler Ryan Zimmerman - BTIG Joshua Jennings - Cowen Madeleine Williams - Wilsons Operator Good day and thank you for standing by and welcome to AVITA Medical Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

AVITA Medical, Inc. (RCEL) Q3 2022 Earnings Call Transcript

VALENCIA, Calif. and MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today reported financial results for the third quarter ended September 30, 2022.

News for AVITA Medical Inc Stock (RCEL)